#Israel #Tel Aviv #Glioblastoma #Spinal Cord Injury #Matricelf

Matricelf's Progress in Spinal Cord Injury Treatment Development

Matricelf Ltd., a leading company in regenerative medicine dedicated to creating personalized, engineered neural tissues, is making significant strides in its development of innovative therapies for spinal cord injury (SCI). Recently, they announced crucial advancements, particularly in preparation for patient enrollment related to their first-in-human clinical study.

On July 9, 2026, Matricelf received an important green light from the Helsinki Committee as well as the Director of Loewenstein Rehabilitation Medical Center in Israel. This authorization permits the company to initiate the collection of blood samples from patients suffering from complete thoracic spinal cord injuries (AIS A, T2–T12). Utilizing these samples, Matricelf aims to generate induced pluripotent stem cells (iPSCs), integral to their groundbreaking personalized autologous neural implant. This implant is designed to replace damaged neural tissues using the patient’s own biological material, minimizing the risk of immune rejection.

The partnership with Loewenstein Medical Center enriches Matricelf’s ability to identify and prepare suitable patients for the clinical study. Given the center's reputation as Israel's premier spinal cord injury rehabilitation facility, the collaboration is set to enhance patient identification while tapping into a specialized clinical team for further support.

“This approval marks a significant stride in our planned transition from preclinical advancements to clinical application,” stated Gil Hakim, CEO of Matricelf. The operational success reflects a methodical approach towards minimizing execution risks associated with entering the clinical phase.

This milestone comes on the heels of several other key achievements for Matricelf, including:

• - Completion of their GLP IND-enabling safety study, which met all defined safety criteria.
• - Initiation of good manufacturing practice (GMP) production processes for their personalized implants.
• - Ongoing studies focused on the therapeutic potential of their platform technology.
• - Continuous collaborations with regulatory bodies to bolster their first-in-human clinical program.

Matricelf’s investigational therapy aims to regenerate neural tissue by harnessing iPSCs from the patient, intertwined with a proprietary extracellular matrix hydrogel sourced from the patient's own omentum. This unique approach strives to provide a rich biological medium for tissue integration and aims at restoring neurological function effectively, illustrating groundbreaking potential in regenerative medicine.

Despite the approval for blood sample collection, it’s important to note that implantation in humans and the overall clinical trial launch require further regulatory scrutiny and ethics committee approvals, including sign-off from the Israeli Ministry of Health.

As Matricelf advances clinically, they remain committed to developing revolutionary therapies that leverage individual biological components to enhance recovery and quality of life for individuals affected by spinal cord injuries.

About Matricelf:
Matricelf is pioneering the regenerative medicine sector by developing innovative, personalized autologous engineered tissue therapies, focusing initially on spinal cord injury with aspirations to broaden applications within regenerative medicine. Their ongoing advancements position them at the forefront of healthcare innovation, with a mission aimed at transforming recovery paradigms for spinal cord injury patients.